Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 3
2(28.6%)
7Total
Phase 2(5)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03210740Phase 2Completed

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Role: lead

NCT03005964Phase 2Completed

Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis

Role: lead

NCT01938599Phase 2Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Role: lead

NCT01353976Phase 3Completed

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

Role: lead

NCT00768599Phase 2Completed

A Study of Econazole Foam 1% in Athlete's Foot

Role: lead

NCT01696799Phase 2Completed

Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years

Role: lead

NCT01358240Phase 3Completed

Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis

Role: lead

All 7 trials loaded